Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of maternal RSVpreF vaccination to prevent RSV lower respiratory tract infection in infants
jRCT2031200167Phase 3Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and pulmonary infection comparing RSVpreF maternal vaccination with Placebo maternal injection (2 arms). Primary endpoints: Reduction in medically attended RSV-associated LRTI through 180 days of life, Reduction in medically attended severe RSV-associated LRTI through 180 days of life and 7 more. Started Oct 2020; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on jRCT2031200167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200167.